Document Detail


Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE.
MedLine Citation:
PMID:  23412597     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The aim of this work was to calculate the radiation absorbed dose to kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors (NETs) of patients treated with (177)Lu-DOTATATE.
METHODS: We enrolled 61 patients (male/female patients, 40/21) with mean age of 48.1 ± 15.3 years affected by different types of NETs diagnosed with (68)Ga-DOTANOC PET-CT and biochemical markers. For radiation protection of kidneys, amino acid mixture (lysine and arginine) was coinfused; 3.7 to 7.4 GBq (100-200 mCi) of (177)Lu-DOTATATE was infused to each patient over 30 minutes. Each patient underwent a series of 9 whole-body scans at 30 minutes (prevoid) and 4, 8, 12, 24, 48, 96, 144, and 168 h. The organs included in dosimetric calculation were kidney, liver, spleen, pituitary gland, and NETs. All dosimetric calculations were done using the OLINDA/EXM 1.0 software.
RESULTS: Physiological uptake of (177)Lu-DOTATATE was seen in all patients in kidneys, liver, spleen, and pituitary gland. Radiation absorbed doses were calculated: 0.57 ± 0.09 mGy/MBq for kidneys, 0.27 ± 0.05 mGy/MBq for liver, 1.17 ± 0.14 mGy/MBq for spleen, 0.058 ± 0.011 mGy/MBq for pituitary gland, and 3.41 ± 0.68 mGy/MBq for NETs.
CONCLUSIONS: The maximum cumulative activity of (177)Lu-DOTATATE that can be safely administered to a patient within permissible renal threshold in our study was found to be 40 GBq (1100 mCi). However, there are considerable interpatient differences in absorbed doses of all organs requiring individualized dosimetry for optimizing tumor dose.
Authors:
Santosh Kumar Gupta; Suhas Singla; Parul Thakral; Chandrasekhar S Bal
Related Documents :
17094087 - Valvular heart disease in parkinson's disease patients treated with dopamine agonists: ...
19855367 - Sweat: a potential marker of clinical activity in panic disorder.
9749797 - Reduction of noradrenaline impairs attention and dopamine depletion slows responses in ...
19039227 - Transient disabling dyskinesias: a predictor of good outcome in subthalamic nucleus dee...
22753867 - Prolonged implantable electrocardiographic monitoring indicates a high rate of misdiagn...
9740087 - Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical nuclear medicine     Volume:  38     ISSN:  1536-0229     ISO Abbreviation:  Clin Nucl Med     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-15     Completed Date:  2013-07-30     Revised Date:  2013-08-30    
Medline Journal Info:
Nlm Unique ID:  7611109     Medline TA:  Clin Nucl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  188-94     Citation Subset:  IM    
Affiliation:
Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Female
Humans
Kidney / radiation effects
Liver / radiation effects
Male
Middle Aged
Neuroendocrine Tumors / radiotherapy*
Octreotide / adverse effects,  analogs & derivatives*,  therapeutic use
Organometallic Compounds / adverse effects*,  therapeutic use*
Organs at Risk / radiation effects*
Pituitary Gland / radiation effects
Radiometry
Spleen / radiation effects
Chemical
Reg. No./Substance:
0/(177lutetium-DOTA(O)Tyr3)octreotate; 0/Organometallic Compounds; 83150-76-9/Octreotide
Comments/Corrections
Erratum In:
Clin Nucl Med. 2013 Jul;38(7):588

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ventilation/Perfusion scanning for acute pulmonary embolism: effect of direct communication on patie...
Next Document:  A mass resulting from cerebral spinal fluid collection of ventriculopleural shunt: radiographic and ...